While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

What is Wegovy? What are its side effects and what does it treat? - Panorama will look at the ‘game changing’ medication but ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...